Osteogenesis Imperfecta Treatment Forecast Report 2025 – Designed for Product & Growth Teams

 Unlock 30% off global market reports with code ONLINE30 — get insights on tariff changes, macro trends, and global economic shifts.

 
 What is the current market size of the osteogenesis imperfecta treatment industry, and what growth rate is it expected to achieve?
 The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.89 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to an increasing number of clinical trials for oi-specific drugs, rising healthcare expenditure in rare disease management, growing focus on personalized and regenerative medicine, increasing availability of genetic counseling and screening, and rising collaborations between pharma and biotech companies.
 
 The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed increasing prevalence of osteogenesis imperfecta, rising awareness and diagnosis rates of rare genetic disorders, growing demand for effective bone health therapies, rising research funding for rare disease treatments, and growing development of monoclonal antibody therapies. Major trends in the forecast period include advancements in monoclonal antibody technology, technological advancements in 3d bone imaging and diagnostics, development of novel drug delivery systems, advancements in stem cell therapy and regenerative treatments, and integration of telemedicine platforms for remote patient management.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24639&type=smp
  
 What are the major drivers contributing to the growth of the osteogenesis imperfecta treatment market?
 The increasing prevalence of osteogenesis imperfecta is expected to propel the growth of the osteogenesis imperfecta treatment market going forward. Osteogenesis imperfecta is a genetic disorder characterized by fragile bones that break easily due to defective or insufficient type I collagen. The rise in osteogenesis imperfecta cases is mainly due to improved genetic testing and diagnostic awareness, leading to better detection of previously overlooked cases. Osteogenesis imperfecta treatment helps by strengthening bones, reducing fracture risk, managing symptoms, and improving mobility and quality of life. For instance, in June 2022, according to the Parliament of the United Kingdom, a UK-based governing body, osteogenesis imperfecta affected around 5,000 people in the UK. Therefore, the increasing prevalence of osteogenesis imperfecta is driving the growth of the osteogenesis imperfecta treatment market.
 
 What are the major market segments driving the growth of the osteogenesis imperfecta treatment industry?
 The osteogenesis imperfecta treatment market covered in this report is segmented –
 
 1) By Treatment Type: Medication, Surgery, Physical Therapy, Lifestyle Modifications
 2) By Drug Class: Teriparatide, Denosumab, Other Drug Classes
 3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Other Routes Of Administration
 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Medication: Bisphosphonates, Teriparatide, Hormone Replacement Therapy, Pain Relievers, Calcium And Vitamin D Supplements
 2) By Surgery: Rodding Surgery, Spinal Fusion Surgery, Fracture Repair Surgery, Joint Replacement Surgery
 3) By Physical Therapy: Strength Training, Range Of Motion Exercises, Aquatic Therapy, Gait Training, Assistive Device Training
 4) By Lifestyle Modifications: Nutritional Counseling, Fall Prevention Strategies, Home Environment Modification, Activity Modification, Patient Education And Support Programs
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/osteogenesis-imperfecta-treatment-global-market-report
 
 What are the key trends shaping the osteogenesis imperfecta treatment market in the forecast period?
 Major companies operating in the osteogenesis imperfecta treatment market are focusing on advanced therapeutics such as sclerostin inhibition therapy to accelerate bone formation and reduce fracture risk in patients with osteogenesis imperfecta (OI). Sclerostin inhibition therapy involves the use of monoclonal antibodies to block sclerostin, a protein that restricts bone growth, thereby promoting increased bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, received Breakthrough Therapy Designation from the FDA for its investigational therapy setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, which in turn stimulates new bone formation and enhances bone strength, aiming to reduce fracture risk in patients with OI Types I, III, and IV aged two years and older.
 
 Who are the key market players contributing to the growth of the osteogenesis imperfecta treatment industry?
 Major companies operating in the osteogenesis imperfecta treatment market are Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, BioSenic SA.
 
 Which regions are leading the growth of the osteogenesis imperfecta treatment market globally?
 North America was the largest region in the osteogenesis imperfecta treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteogenesis imperfecta treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Osteogenesis Imperfecta Treatment Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24639
 
 Need Customized Data On Osteogenesis Imperfecta Treatment Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=24639&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Americas +1 310–496-7795
 Asia +44 2071930708
 Europe +44 7882 955267
 Email us at info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company